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Background: The etiology of exercise-induced pulmonary hypertension (exPH) in systemic sclerosis
(SSc) remains a complex task, as both left ventricle (LV) diastolic dysfunction and pulmonary vascular
disease can contribute to its development. We determined the incidence of exPH in SSc and examined
the association between pulmonary artery systolic pressure (PASP) and tissue Doppler-derived indexes
of pulmonary capillary wedge pressure (PCWP). Methods: Thirty-eight patients with SSc were studied,
using a cycloergometer protocol; 10 were excluded due to resting PH or absence of tricuspid regurgita-
tion (TR); TR and mitral E-wave velocities, LV outﬂow tract time-velocity integral and LV septal E′-wave
were measured before and in peak exercise to calculate cardiac output (CO), PCWP and pulmonary vas-
cular resistance (PVR). Results: Mean age of diagnosis was 57.9 ± 8.9 years. At a mean workload of
64 ± 29 Watts, 48% of patients increased PASP  50 mmHg. PCWP, assessed by the E/e′ ratio, did
not change signiﬁcantly during exercise (10.2 ± 3.1–10.0 ± 5.1; P = NS). Only 3 patients had eleva-
tions of the E/e′ ratio  13 during exercise; 2 of them had an exercise PASP  50 mmHg, yielding a
proportion of exPH due to elevated LV ﬁlling pressures of 2/11 (18%). Patients with exPH had lower
DLCO and had more frequently the diffuse SSc. Conclusion: The elevation of PASP during exercise in
most patients of this cohort seems to be related to a reduced pulmonary vascular reserve, and not to an
increase in PCWP. Further studies are warranted to determine the therapeutic, as well as prognostic
implications of these ﬁndings. (Echocardiography 2013;30:378-384)
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Systemic sclerosis (SSc) is a complex autoim-
mune connective tissue disorder characterized by
widespread vascular lesions and ﬁbrosis of the
skin and internal organs.1 Pulmonary hyperten-
sion (PH) is a common complication of SSc asso-
ciated with a dramatic mortality rate.2 Although
many patients develop PH as a result of pulmo-
nary arteriopathy (pulmonary arterial hyperten-
sion [PAH]), others develop it as a result of
pulmonary ﬁbrosis (group 3 PH) or even chronic
thromboembolic PH (group 4 PH).3 However, a
signiﬁcant number of patients can develop PH
secondary to diastolic dysfunction of the left
ventricle (LV), that can lead to an abnormal
increase in pulmonary artery (PA) pressures, due
to upstream transmission of associated increase
in LV diastolic pressure (pulmonary venous
hypertension [PVH], group 2 PH).4 The differenti-
ation of these subtypes is critical for the correct
management of patients with scleroderma-asso-
ciated PH, as the prognosis and treatment related
to each one of these etiologies is different.5
Timely identiﬁcation of PH and concise char-
acterization of the pathophysiological mecha-
nism involved, especially in its earlier stages, may
favorably alter disease management.6 As the inci-
dence and severity of PH is highly variable, a tool
for early detection and characterization of this
complication would be of value for the identiﬁca-
tion of patients at risk for disease progression.7
Current PH guidelines recommend screening SSc
patients with an annual resting echocardiogram,
as no data ﬁrmly supports the use of exercise
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echocardiography.5 Besides evaluating tricuspid
regurgitation (TR) velocity, a resting echocardio-
gram can identify subtle alterations in right ven-
tricular (RV) function that may have prognostic
impact.8,9
The change in PA systolic pressure (PASP) with
exercise provides a possible tool for detection of
subclinical pulmonary vascular disease4,10,11 and
it has been already used for the identiﬁcation of
abnormal pulmonary vascular responses to exer-
cise in patients with a familial predisposition for
PAH that is not present at rest.12 The use of
newer noninvasive indicators of LV ﬁlling pres-
sures, such as the ratio of mitral E ﬂow-velocity
wave and tissue Doppler mitral annulus e′ early
diastolic velocity (E/e′ ratio) during exercise,13,14
can help to better characterize the mechanisms
of PH in SSc patients. It remains known that in
normal subjects, at an average workload of
170 W and cardiac output (CO) of 20 L/min,
pulmonary capillary wedge pressure (PCWP),
extrapolated by E/e′, remains unchanged as com-
pared with resting baseline.15
We sought to determine the incidence of
exercise-induced PH in SSc patients without rest-
ing PH. Moreover, we hypothesized that diastolic
dysfunction may be associated with a greater
increase in PASP during exercise and that this
impairment in diastolic function can be identiﬁed
by echocardiography.
Methods:
The study included, from September 2010 to
December 2011, 38 consecutive patients, aged
18 or above, with a rheumatologist or internist-
established diagnosis of diffuse or limited SSc
according to standard criteria.1 Patients were
referred as part of their routine follow-up care. All
patients had normal LV systolic function (ejection
fraction >55%) and no echocardiographic
evidence of more than mild valvular disease or
signiﬁcant RV dysfunction. Patients were
excluded from the study if they presented any of
the following criteria: (1) decompensated heart
failure on physical examination, (2) absence of
TR or if the TR velocity could not be determined
accurately, (3) ischemic electrocardiographic
changes occurred during exercise, (4) more than
mildly elevated PASP at rest (TR velocity gradient
superior or equal to 35 mmHg plus estimated
right atrial pressure (RAP) of 5 mmHg) when
evaluated by continuous-wave Doppler echocar-
diography, and (5) evidence of more than mild
pulmonary disease on recent lung function tests
(<1 year old). Patients underwent right heart
catheterization (RHC) only if clinically indicated.
Protocol was approved by the institutional ethics
committee, and all patients gave informed con-
sent.
Study Protocol:
A complete resting echocardiographic examina-
tion was performed immediately prior to exercise.
Special care was given to determine TR velocity.
Evidence (or lack thereof) of congestive heart fail-
ure by physical examination was documented
prior to exercise. Patients were counseled to exer-
cise until they believed they could go no further
and the exercise test was terminated when
patients reached their maximum capacity or the
maximum expected heart rate. A blood sample
was drawn for B-type natriuretic peptide (BNP)
sampling, antinuclear antibodies (ANA), anti-cen-
tromere antibodies (ACA), and anti-topoisomer-
ase I antibodies (Anti-Scl70). Moreover, 2 quality
of life questionnaires were applied: the Stanford
Health Assessment Questionnaire (SHAQ), assess-
ing functional capacity, with a score from 0 to 3,
the higher the score the higher the impairment;
and the Medical Outcomes Study Short Form 36
(MOS SF-36) for assessing quality of life, with a
score from 0 to 100, the higher value reﬂecting
the best quality of life.
Stress Doppler Echocardiography:
A standard echocardiographic examination was
performed by an experienced operator at rest
and during peak exercise. The workload was
increased by 25 W every 2 minutes until toler-
ated or maximal heart rate was attained. Heart
rate and blood pressure were recorded at base-
line and during the last 30 seconds of each work-
load. Doppler echocardiography was performed
with a Vivid 7 ultrasound system (GE Vingmed
Ultrasound, Horten, Norway) on a semi-recum-
bent cycle ergometer (model 1200 EL; Ergoline,
Bitz, Germany). The exercise table was tilted
laterally by 20–30° to the left.
Other operator analyzed the ofﬂine echocar-
diographic data. For the assessment of CO, we
used the product of estimated from LV outﬂow
tract Cross-sectional area and pulsed Doppler
velocity-time integral measurements. Systolic pul-
monary artery pressure (PAP) was estimated from
a transtricuspid gradient calculated from the
maximum velocity (V) of continuous Doppler TR
jet, as 4 9 V2 plus 5 mmHg assigned to RAP.
When needed, contrast was given for more accu-
rate TR velocity assessment. PCWP was estimated
from the E/e′ ratio, with PCWP = 1.9 + 1.24 E/e′.
We considered normal PASP values <30 mmHg
at rest and <50 mmHg during exercise,10
whereas an estimated elevation in LV ﬁlling pres-
sure during exercise was deﬁned as E/e′  13
(corresponding to a PCWP of 18 mmHg).14
Statistical Analysis:
Normal distribution was assessed by the Kol-
mogorov–Smirnov test. If normal distribution
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was conﬁrmed values are expressed as mean ±
standard deviation (SD). Otherwise median, 25th
and 75th percentiles are given. Signiﬁcance was
tested by Student’s t-test in case of normal distri-
bution. Otherwise Mann–Whitney–Wilcoxon test
was carried out. P-values <0.05 were considered
statistically signiﬁcant.
Results:
Feasibility of Exercise Echocardiography in a
SSc Population:
We studied a total of 38 SSc patients consecu-
tively presenting to the rheumatology clinic; of
these, 23 (71.9%) were enrolled and 10 (31.1%)
were excluded (Fig. 1). Eight patients (25.0%)
were excluded due to the absence of a good
quality TR jet, one to poor compliance to the
stress test protocol and one due to the presence
of moderate mitral regurgitation. Mean age was
57.9 ± 8.9 years, with a marked female prepon-
derance (22/23; 95.6% females). All patients
were in sinus rhythm at the time of stress echo-
cardiography. Mean body mass index was
25.0 ± 3.7 kg/m2, mean BNP was 33.7 ±
20.2 pg/dL, and mean DLCO was 95.8 ± 18.0%.
All patients were ANA positive, 63.2% were ACA
positive and almost one third (31.6%) were
Scl70 positive; 20% had diffuse scleroderma
form. The mean scores of SHAQ and SF-36 qual-
ity of life questionnaires were 0.92 ± 0.53 and
59.8 ± 21.5, respectively. Data are shown in
Table I.
Echocardiographic Data at Rest and Peak
Exercise:
Data on exercise echocardiography are shown in
Table II. At rest, at a mean heart rate of
71 ± 13 bpm, the mean PASP was 27.5 ±
4.9 mmHg, and mean CO was 4.7 ± 0.9 L/min.
Regarding diastolic function, mean E/A
was 1.1 ± 0.3, with a deceleration time of
185 ± 43 msec and mean E/e′ was 10.2 ± 3.1,
corresponding to a mean PCWP of 14.0 ± 4.0
mmHg. Pulmonary and PCW pressures variation
with exercise are depicted in Figures 2 and 3. At
a mean peak exercise workload of 64 ± 29 Watts,
heart rate increased to 112 ± 23 bpm and PASP
to 50 ± 11 mmHg, yielding a mean positive vari-
ation of 22.2 ± 9.9 mmHg. At peak exercise, CO
almost doubled to 9.1 ± 2.2 L/min, an increase
of 4.9 ± 2.0 L/min. Regarding LV ﬁlling parame-
ters, mean E/A was 1.2 ± 0.4, with a mean decel-
eration time of 150 ± 47 msec and a mean E/e′
of 10.0 ± 5.1, corresponding to an estimated
PCWP of 14.2 ± 6.3 mmHg.
Changes of PASP and PCWP with Exercise:
Using a PASP  50 mmHg cutoff, 11 patients
(47.8%) were classiﬁed as having exercise-
induced PH. However, if a 40 mmHg cutoff was
used, 20 in 23 (87%) patients would be classiﬁed
as exercise-induced PH. PCWP, as assessed by the
E/e′ ratio, did not change signiﬁcantly during exer-
cise (10.2 ± 3.1–10 ± 5.1, P = NS). Only 3
patients had elevations of the E/e′ ratio  13
during exercise. Two of these 3 patients had an
exercise PASP over 50 mmHg. The proportion of
exercise PH due to elevated PCWP was 2/11
(18%). Figure 3 shows the evolution of echo-
derived PCWP during exercise. One patient had a
very high exercise-induced elevation in E/e′: this
patient underwent a RHC with volume loading
andwas diagnosed as severe diastolic dysfunction.
Discussion:
We studied patients with an established diagnosis
of SSc without relevant pulmonary ﬁbrosis or
known PAH and demonstrated that exercise-
induced PH is a common ﬁnding. The elevation
in PASP in most patients was not accompanied
by a parallel increase in PCWP, as measured by E/
e′ ratio, suggesting that the main mechanism for
exercise-induced PH was low pulmonary vascular
reserve.
The occurrence of PH is one of the main clini-
cal problems in SSc and is now the most com-
mon cause of scleroderma-related death.16 The
differential diagnosis of PH in SSc is wide, includ-
ing PAH, PVH, or PH related to lung ﬁbrosis. In a
cohort of 599 scleroderma patients, Hachulla
et al. demonstrated an prevalence of PAH of
7.9%; interestingly, of the 33 patients identiﬁed
by resting echocardiography as having suspected
PAH, PVH was the cause of PH in 10% of them.17
In the 3-year follow-up of same cohort, the inci-
dence of PVH was the same as the incidence of
PAH (0.61 per 100 patient-years).18 Therefore, it
is crucial to characterize LV ﬁlling pressures at rest
and during exercise, as an elevated PAP can be
caused not only by pulmonary vasculopathy but
also by an increase in pulmonary venous pres-
sure, either at rest or during exercise.19
Figure 1. Selection of scleroderma patients for exercise
echocardiography. PASP = pulmonary artery systolic pressure;
E/e′ = ratio of mitral E ﬂow-velocity wave and tissue Doppler
mitral annulus e′ early diastolic velocity).
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The cause for the inappropriate exercise-
induced increase in PAP in patients with SSc is
still a matter of debate. In normal subjects, the
pulmonary vascular bed is a low-ﬂow, low-resis-
tance system, where an increase in CO, as in
exercise, has very little effect on PAP because
of the recruitment and distension of pulmonary
vessels.20 Interestingly, in SSc target organs,
such as the heart, kidneys, or lungs, an abnor-
mality of “vascular reserve” has been demon-
strated in the absence of signs of organ
dysfunction.21 The loss of the capacity to
enhance blood ﬂow upon high request condi-
tions may therefore be present in very early
stages of the disease; this concept is supported
by pulmonary arterial histology and morphom-
etry analysis, that demonstrates that limited
and diffuse SSc patients had a greater area of
intima and higher percent luminal occlusion
compared with normal controls.22 Moreover,
TABLE II
Echocardiographic Findings at Rest and at Peak Exercise of Systemic Sclerosis Patients
Variable n = 23
Exercise PASP < 50
mmHg (n = 12)
Exercise PASP  50
mmHg (n = 11) P-Value
Workload (Watts) 64.4 ± 28.7 66.7 ± 32.6 61.8 ± 25.2 0.696
Rest HR (per minute) 70.9 ± 12.7 67.9 ± 14.8 74.2 ± 9.7 0.248
Exercise HR, (per minute) 114.7 ± 22.8 110.8 ± 23.5 119 ± 22.2 0.402
Rest PASP (mmHg) 27.6 ± 4.9 24.9 ± 3.7 30.5 ± 4.3 0.003
Exercise PASP (mmHg) 49.9 ± 11 41.7 ± 8 58.8 ± 5.3 0.001
Rest CO 4.6 ± 0.9 3.8 ± 0.6 5.1 ± 0.9 0.037
Exercise CO 9.2 ± 2.1 8.5 ± 2.1 9.9 ± 2.1 0.199
Rest E/e′ 10.2 ± 3.1 9.9 ± 2.2 10.5 ± 4 0.659
Exercise E/e′ 10 ± 5.1 9.4 ± 2 10.5 ± 7.2 0.605
Rest PCWP (mmHg) 14.6 ± 4 14.3 ± 2.8 15 ± 5.2 0.703
Exercise PCWP (mmHg) 12.1 ± 3.2 11.9 ± 2.2 12.2 ± 4.1 0.850
Rest E/A 1.1 ± 0.2 1.1 ± 0.2 1.1 ± 0.3 0.388
Exercise E/A 1.2 ± 0.3 1.3 ± 0.4 1.1 ± 0.1 0.190
Rest DT (msec) 186.2 ± 41.6 180 ± 33.6 193 ± 49.7 0.467
Exercise DT (msec) 151 ± 48 140.3 ± 41.9 165.2 ± 54.2 0.248
TAPSE (mm) 22.7 ± 3.1 27.3 ± 5.3 26.8 ± 4.9 0.567
HR = heart rate; PASP = systolic pulmonary artery pressure; mPAP = mean pulmonary artery pressure; CO = cardiac output;
PCWP = pulmonary capillary wedge pressure; PVR = pulmonary vascular resistance; DT = deceleration time; TAPSE = tricuspid
annular plane systolic excursion.
TABLE I
Clinical Characteristics of Systemic Sclerosis Patients
Variable n = 23
Exercise PASP
< 50 mmHg (n = 12)
Exercise PASP
 50 mmHg (n = 11) P-Value
Age (years) 57.9 ± 8.8 57.8 ± 9.2 57.9 ± 8.9 0.984
Female gender (%) 95.7 91.7 100 0.328
Disease duration (years) 11.1 ± 6.5 11.5 ± 6.9 10.5 ± 6.4 0.765
DLCO (% predicted) 95.8 ± 18.0 106 ± 10.8 88.5 ± 19 0.032
BMI (kg/m2) 25.0 ± 3.7 26.56 ± 3.6 23.6 ± 3.5 0.085
Difuse form (%) 20 100 0 0.043
Antinuclear antibodies (+) (%) 100 100 100 n/a
Anti-centromere antibodies (+) (%) 63.2 50.0 77.8 0.210
Scl-70 (+) (%) 31.6 50.0 11.1 0.069
Stanford Health Assessment Questionnaire 0.92 ± 0.53 0.91 ± 0.68 0.92 ± 0.38 0.938
Short form-36 59.8 ± 21.5 54.4 ± 17.6 64.1 ± 24.2 0.331
BNP (pg/mL) 33.7 ± 20.2 32.7 ± 18.2 34.7 ± 22.9 0.835
PASP = pulmonary artery systolic pressure.
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venular involvement may also be present,
sometimes causing veno-occlusive disease.23
The exercise echocardiogram is a reliable non-
invasive technique to detect latent or exercise-
induced PH not evident by standard resting
Doppler echocardiography.24 In normal subjects,
exercise PASP should be <43 mmHg12; however,
in patients aged 50 years or older, 47% sur-
passed a pulmonary artery mean pressure
(PAMP) of 30 mmHg during maximal exercise.25
Due to very different peak exercise PAP cutoffs, it
is difﬁcult to calculate the real prevalence of PH
in SSc patients and its clinical relevancy.19 It is
also unclear which of the cutoff values (40, 45, or
50 mmHg of PASP) during exercise is clinically
relevant for SSc patients.19 Up to 60% of SSc
patients develop exercise-induced PH when a
cutoff of PASP > 40 mmHg is used,26 this pro-
portion being independent form age.27 Despite
its growing role in the assessment of patients
with pulmonary vascular diseases, the use of
exercise echocardiogram is not recommended in
the latest European PH guidelines due to lack of
validation of the PAMP 30 mmHg cutoff.5 How-
ever, resting and exercise PAMP is correlated with
exercise capacity (6 minute walk test and peak
VO2) in SSc patients,
28 underlining its potential
clinical signiﬁcance. For the sake of speciﬁcity, we
considered abnormal a value of exercise PASP
over 50 mmHg, as in 2 other studies.10,19 In our
population, peak exercise PASP was similar to
that reported by some,27,29 but higher that those
reported by other authors.11,30–32 Differences in
the basal characteristics of the population, exer-
cise protocols and estimated RAP and conse-
quent variations in exercise CO may account for
these disparities.
An elevated PAP can be caused not only by
pulmonary vascular disease but also by an
increase in pulmonary venous pressure due to left
heart disease. This stresses the need of accurately
estimating LV ﬁling pressures when assessing SSc
patients with exercise-induced PH. However, to
date, there is no study assessing LV ﬁlling pres-
sures during exercise by tissue Doppler echocar-
diography in SSc patients. The use of E/e′ as
surrogate marker of PCWP during exercise, the so
called diastolic stress test,33 is based on the fact
that in the absence of cardiac disease, e′ increases
to a similar extent to the increase in mitral E
velocity, and the normal E/e′ ratio essentially is
unchanged with exercise or even reduced,34
paralleling the fact that in normal subjects, the
PCWP rarely surpasses 20 mmHg during exer-
cise.35 Conversely, in patients with impaired
myocardial relaxation, E/e′ increases.13 This
approach was latter validated by invasive pres-
sure measurements14,36 and has signiﬁcant prog-
nostic impact.37,38 We used peak exercise E/e′ to
determine if SSc patients had signiﬁcant eleva-
tions of LV ﬁlling pressures during exercise, there-
fore accounting for the elevation in PASP. In our
population, almost one-ﬁfth of patients who
developed exercise-induced PH had an elevation
of the E/e′ ratio over 13 during peak exercise,
corresponding to a PCW  18, the most com-
monly used cutoff for exercise PVH.27,29 There-
fore, most patients had normal LV ﬁlling
pressures at peak exercise, making low pulmo-
nary vascular reserve the most probable cause for
elevated PAP during exercise in the majority of
cases. The proportion of patients with PH due to
LV disease in our cohort was similar to that
Figure 2. Individual patient-by-patient echo-derived pulmo-
nary artery systolic pressure (PASP).
Figure 3. Individual patient-by-patient ratio of mitral E
ﬂow-velocity wave and tissue Doppler mitral annulus e′ early
diastolic velocity (E/e′) at rest and maximum workload.
PASP = pulmonary artery systolic pressure.
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reported to Steen et al. (13%).29 Two other
recent studies found a higher proportion (38%
and 75%) of PVH among SSc patients.19,30
D’Alto et al.31 also highlighted the association of
subtle LV dysfunction with a greater increase in
PASP with exercise in a recent study, using e′/a′
as a marker of resting LV diastolic dysfunction.
Undoubtedly, a systematic follow-up of these
patients is warranted, to determine if the eleva-
tion of PH during exercise is associated with a
higher incidence of resting PH.
Patients with SSc with no signs of PH at rest
but with exertion dyspnea might undergo
exercise echocardiography as part of their assess-
ment, to undercover the mechanism of exercise
limitation. If signiﬁcant exercise-induced PH is
detected, a closer follow-up of these patients
may be warranted and a program of exercise
training may be implemented.39 To date, there is
no evidence supporting the use of selective
pulmonary vasodilators in this group of
patients.5
Study Limitations:
Our study has some acknowledged limitations,
being a single-center study with a small sample
size. As RHC was not performed in all patients,
the intracavitary pressure values are derived from
echocardiography. However, one of the patients
that had a very signiﬁcant elevation of E/e′ was
later catheterized, conﬁrming the elevation in LV
ﬁlling pressures even at rest.
Conclusion:
In our study, exercise-induced PH was very com-
mon in patients with SSc, even when resting
PASP was normal. The elevation of PASP during
exercise in most patients of this cohort seems to
be related to a reduced pulmonary vascular
reserve, and not to an increase in PCWP. Further
studies are warranted to determine the therapeu-
tic, as well as prognostic implications of these
ﬁndings.
Acknowledgements: We would thank António Duarte and Lili-
ana Alves for technical support and Sónia Cancela for logistics.
References
1. Masi AT: Preliminary criteria for the classiﬁcation of sys-
temic sclerosis (scleroderma). Subcommittee for sclero-
derma criteria of the American Rheumatism Association
Diagnostic and Therapeutic Criteria Committee. Arthritis
Rheum 1980;23:581–590.
2. Hachulla E, Carpentier P, Gressin V, et al: Risk factors for
death and the 3‐year survival of patients with systemic
sclerosis: The French ItinérAIR‐Sclérodermie study. Rheu-
matology (Oxford) 2009;48:304–308.
3. Vachiéry J-L, Coghlan G: Screening for pulmonary
arterial hypertension in systemic sclerosis. Eur Respir Rev
2009;18:162–169.
4. Huez S, Roufosse F, Vachiéry J-L, et al: Isolated right ven-
tricular dysfunction in systemic sclerosis: Latent pulmo-
nary hypertension? Eur Respir J 2007;30:928–936.
5. Galiè N, Hoeper MM, Humbert M, et al: Guidelines for
the diagnosis and treatment of pulmonary hypertension:
The Task Force for the Diagnosis and Treatment of Pul-
monary Hypertension of the European Society of Cardiol-
ogy (ESC) and the European Respiratory Society (ERS),
endorsed by the Internat. Eur Heart J 2009;30:2493–
2537.
6. Galiè N, Rubin L, Hoeper M, et al: Treatment of patients
with mildly symptomatic pulmonary arterial hypertension
with bosentan (EARLY study): A double‐blind, rando-
mised controlled trial. Lancet 2008;371:2093–2100.
7. Condliffe R, Kiely DG, Gibbs JSR, et al: Improved out-
comes in medically and surgically treated chronic throm-
boembolic pulmonary hypertension. Am J Respir Crit Care
Med 2008;177:1122–1127.
8. Ivanovic BA, Tadic MV, Zlatanovic MM, et al: Which fac-
tors impact myocardial function in systemic sclerosis?
Echocardiography 2012;29:307–317.
9. Frea S, Capriolo M, Marra WG, et al: Echo Doppler pre-
dictors of pulmonary artery hypertension in patients with
systemic sclerosis. Echocardiography 2011;28:860–869.
10. Callejas-Rubio JL, Moreno-Escobar E,de laFuente PM,
et al: Prevalence of exercise pulmonary arterial hyperten-
sion in scleroderma. J Rheumatol 2008;35:1812–1816.
11. Alkotob ML, Soltani P, Sheatt MA, et al: Reduced exercise
capacity and stress‐induced pulmonary hypertension in
patients with scleroderma. Chest 2006;130:176–181.
12. Grünig E, Weissmann S, Ehlken N, et al: Stress Doppler
echocardiography in relatives of patients with idiopathic
and familial pulmonary arterial hypertension: Results of a
multicenter European analysis of pulmonary artery pres-
sure response to exercise and hypoxia. Circulation
2009;119:1747–1757.
13. Ha J-W, Oh JK, Pellikka PA, et al: Diastolic stress echocar-
diography: A novel noninvasive diagnostic test for dia-
stolic dysfunction using supine bicycle exercise Doppler
echocardiography. J Am Soc Echocardiogr 2005;18:63–68.
14. Burgess MI, Jenkins C, Sharman JE, Marwick TH: Diastolic
stress echocardiography: Hemodynamic validation and
clinical signiﬁcance of estimation of ventricular ﬁlling
pressure with exercise. J Am Coll Cardiol 2006;47:1891–
1900.
15. Argiento P, Chesler N, Mulè M, et al: Exercise stress echo-
cardiography for the study of the pulmonary circulation.
Eur Respir J 2010;35:1273–1278.
16. Steen VD, Medsger TA: Changes in causes of death in
systemic sclerosis, 1972–2002. Ann Rheum Dis
2007;66:940–944.
17. Hachulla E, Coghlan JG: A new era in the management of
pulmonary arterial hypertension related to scleroderma:
Endothelin receptor antagonism. Ann Rheum Dis
2004;63:1009–1014.
18. Hachulla E, deGroote P, Gressin V, et al: The three‐year
incidence of pulmonary arterial hypertension associated
with systemic sclerosis in a multicenter nationwide longi-
tudinal study in France. Arthritis Rheum 2009;60:1831–
1839.
19. Kovacs G, Maier R, Aberer E, et al: Assessment of pulmo-
nary arterial pressure during exercise in collagen vascular
disease: Echocardiography vs right‐sided heart catheteri-
zation. Chest 2010;138:270–278.
20. Raeside DA, Brown A, Patel KR, et al: Ambulatory pulmo-
nary artery pressure monitoring during sleep and exercise
in normal individuals and patients with COPD. Thorax
2002;57:1050–1053.
21. Pignone A, Mori F, Pieri F, et al: Exercise Doppler echo-
cardiography identiﬁes preclinic asymptomatic pulmo-
nary hypertension in systemic sclerosis. Ann N Y Acad Sci
2007;1108:291–304.
383
Exercise-Induced Pulmonary Hypertension in Scleroderma Patients
22. al-Sabbagh MR, Steen VD, Zee BC, et al: Pulmonary arte-
rial histology and morphometry in systemic sclerosis: A
case‐control autopsy study. J Rheumatol 1989;16:1038–
1042.
23. Dorfmüller P, Humbert M, Perros F, et al: Fibrous remod-
eling of the pulmonary venous system in pulmonary arte-
rial hypertension associated with connective tissue
diseases. Hum Pathol 2007;38:893–902.
24. Vachiery J-L, Pavelescu A: Exercise echocardiography in
pulmonary hypertension. Eur Heart J Suppl 2007;9:H48–
H53.
25. Kovacs G, Berghold A, Scheidl S, Olschewski H: Pulmonary
arterial pressure during rest and exercise in healthy sub-
jects: A systematic review. Eur Respir J 2009;34:888–894.
26. Lau EMT, Manes A, Celermajer DS, Galiè N: Early detec-
tion of pulmonary vascular disease in pulmonary arterial
hypertension: Time to move forward. Eur Heart J
2011;32:2489–2498.
27. Saggar R, Khanna D, Furst DE, et al: Exercise‐induced
pulmonary hypertension associated with systemic sclero-
sis: Four distinct entities. Arthritis Rheum 2010;62:3741–
3750.
28. Kovacs G, Maier R, Aberer E, et al: Borderline pulmonary
arterial pressure is associated with decreased exercise
capacity in scleroderma. Am J Respir Crit Care Med
2009;180:881–886.
29. Steen V, Chou M, Shanmugam V, et al: Exercise‐induced
pulmonary arterial hypertension in patients with systemic
sclerosis. Chest 2008;134:146–151.
30. Ciurzynski M, Bienias P, Irzyk K, et al: Usefulness of echo-
cardiography in the identiﬁcation of an excessive increase
in pulmonary arterial pressure in patients with systemic
sclerosis. Kardiol Pol 2011;69:9–15.
31. D’Alto M, Ghio S, D’Andrea A, et al: Inappropriate
exercise‐induced increase in pulmonary artery pressure
in patients with systemic sclerosis. Heart 2011;97:112–
117.
32. Collins N, Bastian B, Quiqueree L, et al: Abnormal pulmo-
nary vascular responses in patients registered with a sys-
temic autoimmunity database: pulmonary Hypertension
Assessment and Screening Evaluation using stress echo-
cardiography (PHASE‐I). Eur J Echocardiogr 2006;7:439–
446.
33. Oh JK, Park S-J, Nagueh SF: Established and novel
clinical applications of diastolic function assessment
by echocardiography. Circ Cardiovasc Imaging 2011;4:
444–455.
34. Ha JW, Lulic F, Bailey KR, et al: Effects of treadmill exercise
on mitral inﬂow and annular velocities in healthy adults.
Am J Cardiol 2003;91:114–115.
35. Ehrsam RE, Perruchoud A, Oberholzer M, et al: Inﬂuence
of age on pulmonary haemodynamics at rest and during
supine exercise. Clin Sci (Lond) 1983;65:653–660.
36. Talreja DR, Nishimura RA, Oh JK: Estimation of left ven-
tricular ﬁlling pressure with exercise by Doppler echocar-
diography in patients with normal systolic function: A
simultaneous echocardiographic‐cardiac catheterization
study. J Am Soc Echocardiogr 2007;20:477–479.
37. Shim CY, Kim S-A, Choi D, et al: Clinical outcomes of
exercise‐induced pulmonary hypertension in subjects
with preserved left ventricular ejection fraction: Implica-
tion of an increase in left ventricular ﬁlling pressure dur-
ing exercise. Heart 2011;97:1417–1424.
38. Holland DJ, Prasad SB, Marwick TH: Prognostic implica-
tions of left ventricular ﬁlling pressure with exercise. Circ
Cardiovasc Imaging 2010;3:149–156.
39. Mereles D, Ehlken N, Kreuscher S, et al: Exercise and
respiratory training improve exercise capacity and quality
of life in patients with severe chronic pulmonary hyper-
tension. Circulation 2006;114:1482–1489.
384
Baptista, et al.
